We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,918,777 | 16:29:57 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
Date | Subject | Author | Discuss |
---|---|---|---|
21/9/2022 15:05 | I told you yesterday. | netcurtains | |
21/9/2022 15:02 | Can’t believe you’re so brave to keep buying glaxo.I’m in despair at drop in share price.will it recover??. | hopefuldave | |
20/9/2022 15:06 | Risks of Ukraine escalation due to referendums are causing some panic in the FTSE et al. | netcurtains | |
20/9/2022 13:04 | Haleon has posted double-digit revenue growth in its first interim results as an independently-listed company. The group, which became the UK's largest stock market listing in a decade when it spun off from pharma giant GlaxoSmithKline in July, saw revenues jump 13.4 per cent to £5.19billion in the six months to 30 June as adjusted operating profits jumped 12.2 per cent to £1.19billion. Haleon also told investors it believes it is not liable for claims arising from US litigation over heartburn drug Zantac, which has hit pharma shares significantly in recent months amid allegations the compound contains a probable carcinogen. | tradermichael | |
20/9/2022 12:52 | Just added another few earlier this morning. Will it go to 1200 ? If so I will definitely be a buyer. | supermarky | |
18/9/2022 12:09 | Good day uppompeii I'm well in body....... if not mind. Good luck with your portfolio. I've been through the elderly parent phase. I empathise. No grand children as yet. I'm still trading but rarely an overnight hold and certainly no holding over the weekends. | bracke | |
17/9/2022 12:50 | Sorry for the long term holders here what a torrid time.Still hold some via trusts.Chart wise £12 is big support not sure if they trying to get it there. | tim 3 | |
17/9/2022 09:45 | Felicitations bracke, I hope I find you well?Indeed I'm fond of a good chart.This looks like I will buy some, I'm not too concerned about the entry price at this level.Aside from funds, I'm currently holding Aviva (naturally), L&G, M&G, Unilever and just took a punt on Direct Line...reasonable ongoing divi's from those.I just don't have the time to actively trade, elderly parent and grandchildren...both ends of the spectrum. | uppompeii | |
16/9/2022 16:09 | What percentage of GSK turnover is in dollars? | netcurtains | |
16/9/2022 15:30 | True, but I can't help think it looks pretty toppy now. Whereas this.. | rikky72 | |
16/9/2022 12:41 | AZN continues to power ahead...... | spoole5 | |
16/9/2022 08:23 | https://www.google.c | blackhorse23 | |
16/9/2022 07:54 | $1.14 = £1, is amazing for GSK earnings. Quarterly results on 2nd November will make good reading .... :0) | tradermichael | |
14/9/2022 12:34 | Good day uppompeii Long time no speak. "So is this worth a buy?" ==================== At some point yes. Knowing how you like a chart I thought you would appreciate this one SP currently resting on the 78.6% fib. Difficult to avoid the thought that 1200 beckons. The pink dashed line indicates the low in 2015 and 2018 so it may come to the 'rescue'. Best keep an eye on the fib support. GSK DAILY | bracke | |
13/9/2022 13:11 | Jonjo, a good point, thanks. I've tidied up my post now to give the thread more logical continuity! | tradermichael | |
13/9/2022 12:44 | So is this worth a buy? | uppompeii | |
13/9/2022 12:32 | TM you are a victim of 'post hoc ergo propter hoc'. This site loses it integrity by allowing posters to edit after their post has been replied to. Thereby rendering your post meaningless. Shouldn't be allowed. | jonjoneil | |
12/9/2022 09:08 | As the largest consumer healthcare business in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins, Haleon is a global leader in over the counter medicines with a 7.3 percent market share. Market capitalisation of £20bn is unrealistically cheap and is probably worth double that valuation! | tradermichael | |
12/9/2022 08:55 | Yet everyone now knows Haleon is worth less than half that and probably alot less than £20 billion! | paul planet earth | |
12/9/2022 08:43 | Nope: the saving grace is that a WELL-RESPECTED MAN in the industry - the head of Unilevel thinks HLN is worth MORE THAN £50b..... That my friend is something you cannot keep hiding from. | netcurtains | |
12/9/2022 08:40 | Re the Unilever £50bn bid. I think the only saving grace for our Emma is that Unilever shareholder's were not expected to vote through the acquisition at the suggested price. ie the bid wasn't firm and set in stone, still needing to be sold to UNL stockholders. But what a disaster so far Haleon, and GSK. | geckotheglorious | |
12/9/2022 07:47 | ...so you think a MAN who offers £50b is great but you think HLN is worth less than half the £50b.... Your position is so shot full of logical flaws I dont know where to begin. I can no longer take the shorters seriously, they do not know what they are doing. | netcurtains | |
12/9/2022 03:59 | MRF - couldn't have put it better. | unastubbs |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions